Global contract research organisation (CRO), Chiltern, has acquired Integrated Development Associates (IDA), which is a CRO that specialises in integrating Japan and Asia into global drug development.
acquisition puzzle
“The acquisition of IDA is driven by our commitment to establish a substantial presence in all major global markets and support our clients with clinical development capabilities worldwide,” confirmed Jim Esinhart, PhD, CEO of Chiltern. “Japan and Southeast Asia are among the world’s largest and fastest-growing pharmaceutical markets. IDA will enable us to grow in the APAC region through well-established relationships and local expertise and knowledge.”
IDA offers expertise in establishing regulatory and development pathways for Japan and implementing pan Asian clinical trials to achieve Japanese and global regulatory objectives. It is reported that the company’s experience in a range of therapeutic areas and its local knowledge and relationships will enable Chiltern to offer approaches for integrating Japan and Asia into global drug development.
Under the terms of the agreement, IDA will be renamed as IDA, a Chiltern Company, and will do business as a wholly owned subsidiary.
